ERBB2 and cancer: Given the disappointing results with trastuzumab and the kinase inhibitor neratinib in patients with urothelial cancer16,29, we asked whether urothelial tumors classified clinically as ERBB2 amplified had levels of gene amplification similar to that of cancers for which trastuzumab and HER2 kinase inhibitors are standard care.